An Italian neurosurgeon is saying he plans on transplanting a head onto a donor body, not in some distant future, but by the end of 2017.
When Dr. Sergio Canavero first announced his plans a couple of years ago, most people thought he was either crazy, or it was a publicity stunt. Now Canavero says he will put the head of 30-year-old Russian Valery Spiridonov on a donor body in December. Spiridonov suffers from Werdnig-Hoffman disease, which is a form of spinal muscular atrophy.
The surgeon said the procedure would take humanity closer to extending life indefinitely.
Although Canavero insists everything is ready to go, a lot of the details remain murky, and it might still be more fantasy than reality.
Dr. David Albert Jones, the director of the Oxford-based Anscombe Bioethics Centre, says the risks associated with such an attempt are not justifiable.
The center is a Catholic academic institute that studies the moral issues surrounding medicine.
The current scientific and medical consensus is that this experiment has very little chance of success, Jones told Crux, adding the most likely outcome is either death during the operation or survival in a paralyzed state for a few hours or days.
Similar experiments have been done with small animals, to little success. No animal has ever come out of the procedure without being paralyzed, and they all have died soon after.
Jones said the studies are not even advanced enough to attempt the procedure on primates such as monkeys or chimpanzees, let alone a human subject.
There is nothing to suggest that the current proposal for a head transplant is realistic, Jones said, adding even if it were, it would not put mankind on a path to immortality.
People who have received donor organs live longer than they would have done, but they do not live longer, on average, than the average life expectancy of the general population, Jones said.
We will all die.
Jones did warn that if immortality became the goal of a society, this could be a real concern because the quest for unachievable goals can detract from the achievable goals of society, the realistic goals of healthcare, education and social solidarity.
Jones responded to some questions from Crux by email, and told us the scientific and ethical concerns about the proposed procedure.
Crux: Is this even possible with todays technology?
Jones: The idea of a head transplant (or a neck down body-transplant) has been attempted in animals but most animals have either died or have been completely paralyzed and none have lived more than a few days. Given the very poor outcome with mice at the present time it is very difficult to justify attempting this with primates, let alone with humans.
A key challenge is reconnecting the spinal cord. Only if we could finally overcome this problem in patients suffering from spinal cord injury (for example, by the use of gene therapy, stem cells and/or growth factors) would it be realistic to deliberately severe the spinal cord and reconnect the head to a different body.
Thought must also be given to the consequences if the body were to reject the new head. Could the head be kept alive apart from the body, and what kind of existence would this be?
Is such a transplant ethically permitted?
The current scientific and medical consensus is that this experiment has very little chance of success. The most likely outcome is either death during the operation or survival in a paralyzed state for a few hours or days.
The risks are such that it is not justifiable even with consent, but there is an added concern in that it seems likely that the patient has been given misinformation about the realistic prospects for success, and in these circumstances it seems doubtful that consent is properly informed.
It should also be noticed that the operation would not only take great financial and human resources but would also require a donor whose heart, lungs, liver, and/or kidneys could have given real benefits to several patients on the organ transplant waiting list. The opportunity costs would, at the very least, involve extending the suffering of these patients and could involve the death of a patient who might otherwise have been saved.
Many are saying that if such a surgery is successful, it puts humanity on the path to immortality. Should such a goal concern us?
There is nothing to suggest that the current proposal for a head transplant is realistic. If some time in the future the technical problems were overcome, it would not be the path to immortality any more than current, very successful, transplant medicine puts people on a path to immortality. People who have received donor organs live longer than they would have done, but they do not live longer, on average, than the average life expectancy of the general population. We will all die.
How can the Church do more to help people assess the morality of new biotechnologies and medical (or pseudo-medical) procedures?
The goal of immortality is unachievable. There is no need to be concerned therefore about the achievement of this goal. On the other hand if (virtual) immortality became the goal of a society, this could be a real concern because the quest for unachievable goals can detract from the achievable goals of society, the realistic goals of healthcare, education and social solidarity.
The virtue of temperateness is needed if society is to avoid such vain and destructive desires. The Church could do more to promote the virtues of temperateness and humility, which are necessary not only in relation to this issue but in the wider context of the care of creation.
How should the governments involved handle such things, both on a national and international level? I mean, it seems odd that this doctor is even being allowed to attempt this procedure, given the objections from many that the technology has not even been tested properly.
Governments should ensure that experimental surgery is subject to the same level of ethical scrutiny as the clinical trials of drugs or of medical devices. Unfortunately surgery is sometimes given a degree of latitude that leaves patients vulnerable to exploitation. Experimental procedures should not be permitted by a hospital unless and until it has been subject to scientific peer review and has satisfied a clinical ethics committee. It is difficult to see how the current proposal could fulfill such criteria.
Read the original here:
Should a head transplant be allowed to happen? - Crux Now - Crux: Covering all things Catholic
- Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live - November 26th, 2023
- What Is Amyloidosis? All About The Rare Disease That Pervez Musharraf Suffered From - ABP Live - February 8th, 2023
- Autophagic death of neural stem cells mediates chronic stress-induced ... - November 7th, 2022
- Programmed cell death - Wikipedia - November 7th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 4th, 2022
- Canadian Blood Services Stem Cells for Life - September 4th, 2022
- Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live - September 4th, 2022
- From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope - September 4th, 2022
- Scientists unlock the key to immortality in jellyfish - Syfy - September 4th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients... - September 4th, 2022
- Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML - Targeted Oncology - September 4th, 2022
- Wanted murder suspect John Belfield believed to still be in the UK as two more arrested over death of Thomas Campbell - The Manc - September 4th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Can minds persist when they are cut off from the world? - Livescience.com - July 8th, 2022
- Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population - Cancer Network - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- How abortion ruling could affect IVF and embryonic research - The Almanac Online - July 8th, 2022
- This Morning viewers 'in tears' after boy meets donor who saved his life - Devon Live - July 8th, 2022
- Alpena detective: 'Good people out there' | News, Sports, Jobs - Alpena News - July 8th, 2022
- 'I miss my best friend': Five-year-old runs 10k to honour girl who died from rare brain tumour - Teesside Live - July 8th, 2022
- Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by... - July 8th, 2022
- Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc - Yahoo Finance - July 8th, 2022
- A New Strategy Could Turn the Tide in Stem Cell GVHD - Medical Device and Diagnostics Industry - January 17th, 2022
- Vertex type 1 diabetes vs stem cell therapy - The Boar - January 17th, 2022
- Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT - AJMC.com Managed Markets Network - January 17th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 17th, 2022
- Psaki demolishes Doocy with stats as he tries to claim covid now an illness of the vaccinated - newsconcerns - January 17th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 17th, 2022
- Who does donated blood that's direly needed help? - WTOP - January 17th, 2022
- Places Where Omicron is Most Contagious Eat This Not That - Eat This, Not That - January 17th, 2022
- UHN and U of T receive $24-million federal grant for transplant research - News@UofT - January 17th, 2022
- Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes | Scientific... - January 17th, 2022
- Stem cells in cancer therapy: opportunities and challenges - January 1st, 2022
- Life After Brain Death: Is the Body Still 'Alive'? | Live ... - January 1st, 2022
- Autologous Adult Stem Cells in the Treatment of Stroke | SCCAA - Dove Medical Press - January 1st, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 1st, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 1st, 2022
- Upregulated expression of actin-like 6A is a risk factor | CMAR - Dove Medical Press - January 1st, 2022
- COVID-19 Takes a Toll on People with Blood Cancers and Disorders - Cancer Health Treatment News - January 1st, 2022
- Mental health disorders and heart diseases - Rising Kashmir - January 1st, 2022
- Research breakthrough could mean better treatment for patients with most deadly form of brain tumor - EurekAlert - October 26th, 2021
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable... - October 26th, 2021
- European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Galveston County Daily News - October 26th, 2021
- Everything You Need To Know About COVID Booster Shots - Colorado Times Recorder - October 26th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Will humans ever be immortal? - Livescience.com - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - ABC 12 News - October 5th, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 5th, 2021
- Skeletons' broken clavicles tell a centuries-old tale of humans and horses - Massive Science - October 5th, 2021
- Environmental Factor - August 2021: Extramural Papers of the Month - Environmental Factor Newsletter - August 4th, 2021
- Role of traumatic brain injury in the development of glioma | JIR - Dove Medical Press - August 4th, 2021
- Targeted Therapeutics Market: Increase in Incidence of Cancer to Drive Global Market - BioSpace - August 4th, 2021
- Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Ca | CMAR - Dove Medical Press - August 4th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 7th, 2021
- Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver - Science Advances - June 7th, 2021
- Cancer research: New advances and innovations - Medical News Today - June 7th, 2021
- Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer - Targeted Oncology - June 7th, 2021
- Merck's KEYTRUDA Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal... - June 7th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 14th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV (enfortumab vedotin-ejfv) in Patients with Previously... - February 14th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 14th, 2021
- The drug treatments offering the best hope of a way out of the Covid crisis - Telegraph.co.uk - February 14th, 2021
- In the war against Covid, an arsenal of drugs is on the way - Telegraph.co.uk - February 14th, 2021
- Kat Wests husband, Jeff West, sentenced to 16 years in wifes death - AL.com - February 9th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 9th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 9th, 2021
- [Full text] Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor f | CMAR - Dove Medical Press - February 9th, 2021
- West Belfast woman to be remembered in special TV documentary - Belfast Live - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 29th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 29th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 29th, 2021
- Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances - January 29th, 2021